GENETICALLY-DETERMINED DRUG-METABOLIZING ACTIVITY AND DESIPRAMINE-ASSOCIATED CARDIOTOXICITY - A CASE-REPORT

被引：26

作者：

BLUHM, RE

WILKINSON, GR

SHELTON, R

BRANCH, RA

机构：

[1] VANDERBILT UNIV,DEPT PSYCHIAT,NASHVILLE,TN 37232

[2] UNIV PITTSBURGH,MED CTR,CTR CLIN PHARMACOL,PITTSBURGH,PA 15260

[3] VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 1993年 / 53卷 / 01期

关键词：

D O I：

10.1038/clpt.1993.13

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：89 / 95

页数：7

共 30 条

[1]

ARNS PA, 1990, HEPATOLOGY, V12, P977

[2]

ARNS PA, IN PRESS CLIN PHARM

[3] THE DEBRISOQUINE HYDROXYLATION TEST PREDICTS STEADY-STATE PLASMA-LEVELS OF DESIPRAMINE [J].

BERTILSSON, L ;

ABERGWISTEDT, A .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 15 (03) :388-390

[4] TRICYCLIC ANTIDEPRESSANT OVERDOSE - INCIDENCE OF SYMPTOMS [J].

BIGGS, JT ;

SPIKER, DG ;

PETIT, JM ;

ZIEGLER, VE .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1977, 238 (02) :135-138

[5]

BLUHM R, 1991, CLIN PHARMACOL THER, V49, P157

[6] ROLE OF P450IID6, THE TARGET OF THE SPARTEINE-DEBRISOQUIN OXIDATION POLYMORPHISM, IN THE METABOLISM OF IMIPRAMINE [J].

BROSEN, K ;

ZEUGIN, T ;

MEYER, UA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (06) :609-617

[7] FLUOXETINE AND NORFLUOXETINE ARE POTENT INHIBITORS OF P450IID6 - THE SOURCE OF THE SPARTEINE DEBRISOQUINE OXIDATION POLYMORPHISM [J].

BROSEN, K ;

SKJELBO, E .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (01) :136-137

[8] CARDIOVASCULAR EFFECTS OF TRICYCLIC AND TETRACYCLIC ANTIDEPRESSANTS [J].

BURCKHARDT, D ;

RAEDER, E ;

MULLER, V ;

IMHOF, P ;

NEUBAUER, H .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1978, 239 (03) :213-216

[9]

CARR K, 1978, BRIT J CLIN PHARMACO, V6, P421, DOI 10.1111/j.1365-2125.1978.tb04606.x

[10]

CRAMMER JL, 1969, PSYCHOPHARMACOLOGIA, V15, P207

← 1 2 3 →